Biosynthetic pathways for vaccine production involve using biological systems, such as bacteria, yeast, or mammalian cells, to synthesize components required for vaccine formulations. These pathways allow for the mass production of antigens, proteins, or other biologically active substances that are key ingredients in vaccines. Advances in biotechnology have made it possible to engineer microorganisms or cells to produce large quantities of vaccine components quickly and efficiently. For instance, recombinant DNA technology can be used to introduce genes that code for antigens from a pathogen into a host cell, prompting it to produce the antigen for vaccine use. This method is not only cost-effective but also reduces the need for traditional methods like growing pathogens in culture, ensuring both safety and scalability. Biosynthetic pathways continue to evolve, providing more sustainable, rapid, and flexible options for vaccine production, particularly in response to emerging infectious diseases.
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, Italy
Ayesha Zahid
Griffith University, Australia
Livia Daflon Silva
Federal University of State of Rio de Janeiro, Brazil
Neha Bhandari
Chitkara University, IndiaSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States